Naproxen / Naprosyn / Anaprox
- NSAIA (member of the arylacetic acid group);
- for symptomatic RA, bone pain;
- primary dysmenorrhea, acute tendinitis and bursitis, mild to moderate pain:
- typical dose: 250 mg PO bid or 500 mg PO bid (500-1250 mg/24hr PO divided bid);
- available in 250, 375, or 500 mg capsules;
- Naprelan 375 or 500 mg: slow release form;
- for Acute Gout: Naprosyn 750mg PO initially, then 250mg PO q8h til attack has subsided;
- alternatively, try Anaprox 825mg initially then 275mg q8h til attack has subsided;
- Juvenile Rheumatoid arthritis: 10 mg/kg/24hrs PO to max dose of 1000
mg/24 hrs divided bid; supplied: tabs: 250mg, 375mg, 500mg;
- aontraindicated: allergic reactions to ASA or NSAIA;
- use with caution in patients with h/o of GI disease, impaired renal function, liver disease, CHF, elderly, diuretics;
- metabolized primarily in the liver to inactive metabolites;
- no dosage adjustment is required w/ renal insufficiency
References for Naprosyn:
Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients.
The clinical effect of naproxen sodium after arthroscopy of the knee: a randomized, double-blind, prospective study.
Original Text by Clifford R. Wheeless, III, MD.
Last updated by Data Trace Staff on Monday, July 30, 2012 4:37 pm